Alzheimer Disease Clinical Trials in Anaheim, California

5 studies are recruiting for alzheimer disease in Anaheim, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

    The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who c…

    Stage
    Phase 3
    Ages
    55 to 90
    Site
    Local Institution - 1657, Anaheim, California
    Locations
    252 in total
    Run by
    Bristol-Myers Squibb
  2. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

    Stage
    Phase 3
    Ages
    55 to 90
    Site
    Advanced Research Center (ARC) - Anaheim, Anaheim, California
    Locations
    162 in total
    Run by
    Bristol-Myers Squibb
  3. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

    This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

    Stage
    Phase 2
    Ages
    55 to 90
    Site
    Local Institution - 0017, Anaheim, California
    Locations
    78 in total
    Run by
    Celgene
  4. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

    Stage
    Phase 2
    Ages
    55 and older
    Site
    Advanced Research Center, Inc, Anaheim, California
    Locations
    67 in total
    Run by
    Intra-Cellular Therapies, Inc.
  5. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

    Stage
    Phase 3
    Ages
    55 to 90
    Site
    Advanced Research Center, Inc., Anaheim, California
    Locations
    293 in total
    Run by
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.